SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit of -$318K in Q1 FY2026
Q1 FY2026 gross profit was -$318K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (612K) USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (612K) | — |
Gross Profit vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $6.27B USD | +11.6% | +6.6% | 57.3% | |
| LTM Jun 2026 | $3.04B USD | +9.3% | +7.5% | 57.2% | |
| LTM Jun 2026 | $484.88M USD | +46.7% | +22.5% | 79.1% | |
| LTM Apr 2026 | $221.94M USD | +7.4% | -6.5% | 76.4% | |
| LTM Mar 2026 | $98.18M USD | -7.9% | +69.0% | 77.0% | |
| LTM Mar 2026 | $68.55M USD | +2.5% | +4.2% | 86.2% | |
| LTM Mar 2026 | $45.4M USD | -16.1% | -1.2% | 87.2% | |
| LTM Mar 2026 | $5.83M USD | -88.9% | -4.0% | 76.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | -$612K USD | — | — | — |
| LTM Mar 2026 | -CHF 14.56M CHF | — | — | 2889.4% | |
| Peer median (excluding SGP) | — | +5.0% | +5.4% | 77.0% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.